Searched for
ASTELLAS PHARMA
Molecule glue drugs shake up cancer care, draw big moneyHarvard-born idea doubles survival in trials, triggers pharma frenzy as cos race to target 'undruggable' proteins with next-gen glue therap...- Zydus settles US Mirabegron patent dispute with Astellas for $120 millionZydus Lifesciences and its US subsidiary have settled patent litigation with Astellas Pharma over Astellas' Myrbetriq. Zydus will pay Astel...
- Lupin clears Mirabegron patent dispute with Astellas in $90 million deal, secures US sales continuityDrugmaker Lupin has settled a patent infringement dispute with Astellas Pharma over its Mirabegron product for $90 million. The agreement i...
- Japan's Nikkei falls as tech shares drag; Astellas surgesJapan's Nikkei index saw red on Thursday as technology stocks faltered, raising flags over the hefty investments tied to Artificial Intelli...
- How an executive's arrest struck a blow to Japan-China businessThe employee of drugmaker Astellas Pharma, as well as other Japanese imprisoned or under criminal probes in China, would probably be among ...
- China says detained employee of Japan firm suspected of espionage activities"This Japanese citizen is suspected of engaging in espionage activities," Mao said, adding that China had notified the Japanese embassy in ...
- Nikkei closes 1% down; Japan shares end lower on profit-booking, drugmakers limit lossesThe Nikkei share average ended 0.99 per cent lower at 28,860.08, while the broader Topix fell 1.26 per cent to 1,922.98.
- Strides Pharma Science arm gets USFDA nod for drug to treat overactive bladderThe approved product is a generic version of Vesicare tablets of Astellas Pharma US, Inc.
- Alembic Pharma gets USFDA nod for overactive bladder treatment drugThe company has received approval from the USFDA for its abbreviated new drug application (ANDA) Solifenacin Succinate tablets in the stren...
- Nikkei retreats from 4.5-month high; Canon slumps on profit warningThe Nikkei share average dropped 0.84 per cent to 22,090.12, after touching the highest level since early December on the previous day.
- Glenmark Pharma's overactive bladder drug gets USFDA nodAccording to IMS Health April 2017 sales data, the market for Vesicare tablets, 5 mg and 10 mg, saw annual sales of approximately USD 1.1 b...
- Lupin arm in pact to distribute anti-depressant drug in JapanLupin President Dr. Fabrice Egros said the Astellas agreement reinforces Kyowa's transition toward a hybrid pharmaceutical specialty care c...
- Lupin appoints Martin Mercer as head of Latin American businessThe Latin American region is a market of strategic focus for the company and one of the fastest growing pharmaceutical markets globally, sh...
- Glenmark Generics Inc files law suit to enforce licence pactThe agreement is with Triax Pharmaceuticals, Astellas Pharma Europe BV and Astellas Pharma International BV.
- Glenmark gets USFDA nod for skin infections creamGlenmark Pharmaceuticals received approval from USFDA for its generic Hydrocortisone Butyrate Cream used for treating skin infections.
- Glenmark settles patent suit in US over skin infection creamGlenmark Pharma said it has entered into a agreement with Triax and Astellas to resolve a patent infringement case in the US.
- Astellas aims to emerge top player in transplantationJapan’s second-largest pharma company, the $10-billion Astellas Pharma, intends to emerge as a niche player in India.
- Astellas Pharma Q1 profit falls on R&D costsAstellas Pharma Inc Japan's second-largest drug maker, said on Friday its quarterly operating profit fell 5 percent on higher research and ...
- GSK enters into agreement with Japan-based Astellas PharmaDrug firm GlaxoSmithkline Pharmaceuticals on Monday said it has enter into a collaboration with the Japan-based Astellas Pharma Inc for sel...
- Lupin reaches out-of-court settlement with Abbott on OmnicefDomestic pharma company Lupin has reached an out-of-court settlement with US pharma major Abbott and Japan’s Astellas Pharma for the market...
Load More
